Researchers from NeuroActiva, Inc. presented results of their randomized, double-blind, placebo-controlled phase 2A clinical trial of NA-831.
Tramiprosate Associated With High Response, Favorable Safety in APOE ε4 Homozygotes With Mild Alzheimer'sJuly 27, 2018
Researchers assessed individual patient responses as well as overall response rates to oral tramiprosate and the effect of response on clinical outcomes.
The study assessed the pharmacokinetics and pharmacodynamics of 2 doses of oxaloacetate in patients with Alzheimer disease.
Initial data from Study 201, as announced in December 2017, showed BAN2401 did not meet the primary endpoint.
Existing data from the the UK Clinical Practice Research Datalink (CPRD) and 3 clinical studies of PwD were used to evaluate the association between Z-drug administration and the incidence of adverse events.
Participants in this study were part of the Indianapolis-Ibadan Dementia Project that took place from 1992 to 2011 and were assessed for dementia every second or third year during follow-up.
Pimavanserin is currently approved in the United States for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
The researchers conducted a 13-week study that included 162 individuals with advanced dementia and considerable depression residing in nursing homes in Norway.
Although treatment with nabilone significantly improved agitation, cognition, and nutrition, the authors cautioned that sedation should be closely monitored.
Drinking sugary beverages has been previously linked to markers of preclinical Alzheimer disease, but the risk associated with consuming added sugars is not established.
In the previous SPRINT study, researchers compared an intensive BP reduction strategy (target systolic BP <120 mmHg) vs standard BP reduction strategy (target systolic BP <140 mmHg).
Citicoline Plus Memantine Superior to Memantine Alone for Improving Cognition in Alzheimer's DementiaJuly 25, 2018
Patients in the combination treatment arm experienced a greater increase in MMSE scores between baseline and at 6 months compared with those receiving memantine monotherapy.
Study results showed that most common NSAIDs, including aspirin, ibuprofen, naproxen, and celecoxib did not alter cognitive degeneration in patients with mild cognitive impairment or Alzheimer disease.
There was a significant relationship between plasma levels of eicosapentaenoic acid and Alzheimer disease dementia.
The researchers investigated whether the potential relationship between pregnancy and AD risk was linked to an immunologic mechanism.
Given the lack of differences seen via the NIS, the authors suggested that subjective questionnaires may not be a trustworthy method to assess possible statin-associated cognitive deficits.
Participants were drawn from the Health and Retirement Study, which provided multiple observations, genetic information, and previous alcohol use.
High-dose donepezil is currently indicated for patients with Alzheimer disease who have poor response to the lower dose.
Magnetic resonance imaging scans revealed smaller total brain tissue volume and a significant decrease in white matter volume in participants with prediabetes.
Individuals who underwent 2 to 5 years of hormone replacement therapy experienced the greatest risk reduction.
BI 409306 is a novel selective phosphodiesterase-9A inhibitor being examined for its safety, efficacy, and tolerability in patients with prodromal and mild Alzheimer disease.
In a previous study, SCarlet RoAD, gantenerumab had demonstrated a dose-dependent effect on CSF tau species.
Affected life expectancy was characterized for each patient using determinants such as sex, APOE genotype, solitary-living, duration of AD, age at onset, years of education, concomitant medications, activities of daily living, cognitive functioning, and rate of decline.
Currently, there are no US consensus on best clinical practice guidelines that incorporate multispecialty recommendations for evaluating cognitive impairment that are thought to be due to Alzheimer's disease and Related Dementias (ADRD) for use by physicians and nurse practitioners.
The analysis suggests a beneficial effect of aducanumab on functional and cognitive domain scores in adults with Alzheimer disease.
Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available MedicationsJuly 22, 2018
Funding needs to be more widely available to help implement these effective nonpharmacologic interventions.
Memantine Plus Cholinesterase Inhibitors Improves Psychosis, Neurobehavioral Symptoms in Alzheimer DiseaseJuly 22, 2018
Investigators pooled data from patients from 3 phase 3, 24-week, randomized, placebo-controlled trials of MEM in patients with Alzheimer disease receiving concurrent ChEIs.
The genetically-mediated effects of angiotensin-converting enzyme (ACE) inhibitors showed an improvement in cognition in patients with Alzheimer disease dementia but not in functionality.
Adults with depressive symptoms and apathy in middle and late life were at a higher risk for conversion to mild cognitive impairment (MCI) and dementia.
Findings from cross-sectional analyses showed that following a Western dietary pattern was associated with more severe Alzheimer disease neuropathologic variations in older adults.
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Drug Prices Increase More Than Expected After Shortages
- Potentially Inappropriate Opioid Prescribing Tied to Overdose
- Loss of Function Variants in LRKK1 and LRKK2 Not Linked to Parkinson Disease
- Scribes Improve Physician Workflow, Patient Interaction